232 related articles for article (PubMed ID: 35582833)
1. New treatments and new assessment instruments for Hidradenitis suppurativa.
van Straalen KR; Ingram JR; Augustin M; Zouboulis CC
Exp Dermatol; 2022 Sep; 31 Suppl 1(Suppl 1):33-39. PubMed ID: 35582833
[TBL] [Abstract][Full Text] [Related]
2. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.
Thorlacius L; Garg A; Riis PT; Nielsen SM; Bettoli V; Ingram JR; Del Marmol V; Matusiak L; Pascual JC; Revuz J; Sartorius K; Tzellos T; van der Zee HH; Zouboulis CC; Saunte DM; Gottlieb AB; Christensen R; Jemec GBE
Br J Dermatol; 2019 Sep; 181(3):483-491. PubMed ID: 30724351
[TBL] [Abstract][Full Text] [Related]
3. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.
Garg A; Zema C; Ciaravino V; Rolleri R; Peterson L; Garcia L; Massaro T; Jemec GBE; Kirby JS; Thorlacius L; Ingram JR
JAMA Dermatol; 2023 Jun; 159(6):606-612. PubMed ID: 37099284
[TBL] [Abstract][Full Text] [Related]
5. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.
Tzellos T; van Straalen KR; Kyrgidis A; Alavi A; Goldfarb N; Gulliver W; Jemec GBE; Lowes MA; Marzano AV; Prens EP; Sayed CJ; van der Zee HH; Zouboulis CC
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):395-401. PubMed ID: 36184889
[TBL] [Abstract][Full Text] [Related]
7. Convergent Validity of Suffering and Quality of Life as Measured by The Hidradenitis Suppurativa Quality of Life.
Kursawe Larsen C; Kjaersgaard Andersen R; Kirby JS; Tan J; Saunte DML; Jemec GBE
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1577-1581. PubMed ID: 33539563
[TBL] [Abstract][Full Text] [Related]
8. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process.
Ingram JR; Hadjieconomou S; Piguet V
Br J Dermatol; 2016 Aug; 175(2):263-72. PubMed ID: 26873867
[TBL] [Abstract][Full Text] [Related]
9. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.
van Straalen KR; Tzellos T; Alavi A; Benhadou F; Cuenca-Barrales C; Daxhelet M; Daoud M; Efthymiou O; Giamarellos-Bourboulis EJ; Guillem P; Gulliver W; Jemec GBE; Katoulis A; Koenig A; Lazaridou E; Lowes MA; Marzano AV; Matusiak L; Molina-Leyva A; Moltrasio C; Pinter A; Potenza C; Prens EP; Romaní J; Saunte DM; Sayed C; Skroza N; Stergianou D; Szepietowski JC; Trigoni A; Vilarrasa E; Kyrgidis A; Zouboulis CC; van der Zee HH
Dermatology; 2023; 239(3):362-367. PubMed ID: 36630943
[TBL] [Abstract][Full Text] [Related]
10. Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.
Garg A; Zema C; Kim K; Gao W; Chen N; Jemec GBE; Kirby J; Thorlacius L; Villumsen B; Ingram JR
Br J Dermatol; 2022 Aug; 187(2):203-210. PubMed ID: 35599448
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
12. Automatic International Hidradenitis Suppurativa Severity Score System (AIHS4): A novel tool to assess the severity of hidradenitis suppurativa using artificial intelligence.
Hernández Montilla I; Medela A; Mac Carthy T; Aguilar A; Gómez Tejerina P; Vilas Sueiro A; González Pérez AM; Vergara de la Campa L; Luna Bastante L; García Castro R; Alfageme Roldán F
Skin Res Technol; 2023 Jun; 29(6):e13357. PubMed ID: 37357665
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
Zouboulis CC; Tzellos T; Kyrgidis A; Jemec GBE; Bechara FG; Giamarellos-Bourboulis EJ; Ingram JR; Kanni T; Karagiannidis I; Martorell A; Matusiak Ł; Pinter A; Prens EP; Presser D; Schneider-Burrus S; von Stebut E; Szepietowski JC; van der Zee HH; Wilden SM; Sabat R;
Br J Dermatol; 2017 Nov; 177(5):1401-1409. PubMed ID: 28636793
[TBL] [Abstract][Full Text] [Related]
14. Electronic Patient-Reported Outcomes in Hidradenitis Suppurativa: Content Validity and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary, Hidradenitis Suppurativa Symptom Questionnaire, and Hidradenitis Suppurativa Quality of Life Questionnaire.
Ingram JR; Ciaravino V; Rolleri R; Pansar I; Dias-Barbosa C; Kirby JS
Dermatology; 2024; 240(1):65-76. PubMed ID: 37820596
[TBL] [Abstract][Full Text] [Related]
15. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa.
Chernyshov PV; Zouboulis CC; Tomas-Aragones L; Jemec GB; Svensson A; Manolache L; Tzellos T; Sampogna F; Pustisek N; van der Zee HH; Marron SE; Spillekom-van Koulil S; Bewley A; Linder D; Abeni D; Szepietowski JC; Augustin M; Finlay AY
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1633-1643. PubMed ID: 31037773
[TBL] [Abstract][Full Text] [Related]
16. Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment.
Goldfarb N; Lowes MA; Butt M; King T; Alavi A; Kirby JS
Br J Dermatol; 2021 May; 184(5):905-912. PubMed ID: 32969027
[TBL] [Abstract][Full Text] [Related]
17. Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa.
Kimball AB; Ganguli A; Fleischer A
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2254-2256. PubMed ID: 29959796
[TBL] [Abstract][Full Text] [Related]
18. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
[TBL] [Abstract][Full Text] [Related]
19. Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa.
Hasan SB; Gendra R; James J; Morris D; Orenstein LAV; Ingram JR
Br J Dermatol; 2022 Dec; 187(6):846-854. PubMed ID: 35962565
[TBL] [Abstract][Full Text] [Related]
20. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials.
Kirby JS; Thorlacius L; Villumsen B; Ingram JR; Garg A; Christensen KB; Butt M; Esmann S; Tan J; Jemec GBE
Br J Dermatol; 2020 Aug; 183(2):340-348. PubMed ID: 31705538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
